Latest Breaking News On - Axel hoos - Page 1 : comparemela.com

Rx Rundown: Novartis, Goldman Sachs, Klick Health and more

Check out this week’s medical marketing news, people on the move and industry chatter.

United statesCity ofUnited kingdomPaulette mccarronAstellas pharmaAmy zachariasYonatan adiriEli lillyDudley bakerTim jonesPaul ginesteGeoff martinVerona pharmaAdam friedmanPaddi hurleyEvan bograd

Axel Hoos and Michael Streit depart Scorpion

Axel Hoos and Michael Streit depart Scorpion
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

United statesAdam friedmanJerica jacksonPierre fabreMark chaoMichael streitAxel hoosTensixteen bioScorpion therapeuticsChief medical officer michael streitBefore scorpionRaze therapeuticsVivid biosciences

Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023

Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesAxel hoosFrancesco hofmannPierre fabre laboratorieDarrin stuartEuropean organisation for researchScorpion therapeutics incProduct serviceAmerican association for cancer researchPierre fabre foundationNational cancer instituteHead of researchTherapeutics presents preclinical dataPrecision oncologyPierre fabre laboratoriesAmerican association

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Axel hoosMichael streitEric ducournauPierre fabre laboratorieBiomarker researchScorpion therapeutics incPierre fabre foundationProduct serviceLocally advancedMetastatic non small cell lungPrecision oncologyPierre fabre laboratoriesChief executive officerPierre fabreChief medical officerResponse evaluation criteria in solid tumors

Scorpion Therapeutics announces first patient dosed in breast cancer trial

Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.

Axel hoosMichael streitPrecision oncologyClinical developmentPreclinical researchDrug deliveryAtient centricityLinical evolutionPis active pharmaceutical ingredientsHasei iiPrecision medicineData managementClinical trial